PFE: Financial results

Item 2.02 Results of Operations and Financial Condition On November 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description Exhibit 99 Press Release of Pfizer Inc. dated November 3, 2026 , reporting Pfizer’s financial results for the third quarter of 2026. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. EXHIBIT INDEX Exhibit No. Description 99 Press Release of Pfizer Inc. dated November 3, 2026, reporting Pfizer’s financial results for the third quarter of 2026. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Sec